A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis
-
- Endo Jin
- Department of Cardiology, Keio University School of Medicine
-
- Sano Motoaki
- Department of Cardiology, Keio University School of Medicine
-
- Izumiya Yasuhiro
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine
-
- Tsujita Kenichi
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
-
- Nakamura Kazufumi
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
-
- Tahara Nobuhiro
- Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine
-
- Kuwahara Koichiro
- Department of Cardiovascular Medicine, Shinshu University School of Medicine
-
- Inomata Takayuki
- Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital
-
- Ueda Mitsuharu
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
-
- Sekijima Yoshiki
- Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
-
- Ando Yukio
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
-
- Tsutsui Hiroyuki
- Department of Cardiovascular Medicine, Kyusyu University
-
- Isobe Mitsuaki
- Sakakibara Heart Institute
-
- Fukuda Keiichi
- Department of Cardiology, Keio University School of Medicine
Abstract
<p>Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.</p>
Journal
-
- Circulation Journal
-
Circulation Journal 84 (1), 15-17, 2019-12-25
The Japanese Circulation Society